Retraction: Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCullough PA, Risch H: Real-world clinical outcomes of ivermectin and mebendazole in cancer patients (2026)

Peer-Reviewed Study · Editor, Anticancer Research · October 2026

Editor et al., 2026-10: Retraction notice withdrawing the Hulscher et al. ivermectin/mebendazole cancer cohort because the composite clinical-benefit measure was not comparable across survey waves and could not support a therapeutic conclusion.

the Editor of Anticancer Research retracts the above article because methodological and analytical problems undermine the reliability of its central clinical-benefit conclusions.

5877

Editor et al., 2026-10: Retraction notice withdrawing the Hulscher et al. ivermectin/mebendazole cancer cohort because the composite clinical-benefit measure was not comparable across survey waves and could not support a therapeutic conclusion. C5. Grounds, in the notice's own words: disease status recorded with two categories at baseline and four at follow-up; no comparable pretreatment status; no defined reference point for change; no duration criterion for stability; no participant-level linkage between waves; no baseline NED measure; the representativeness analysis compared overlapping groups. The notice states: 'No allegation of research misconduct is made' and that the decision does not rest on arithmetic miscalculation, and that 'The authors dispute the grounds for retraction and propose correction as an alternative.' pdf_url above is the journal's PDF path as printed in the article page metadata but returned an HTML challenge to an automated fetch during this run – the quotable text was read from the HTML article page; treat a direct-PDF check as outstanding. Excerpt from the notice body. Study type: other.